Thomas Jefferson University

Jefferson Digital Commons
Center for Translational Medicine Faculty
Papers

Center for Translational Medicine

October 2008

Deletion of GSK-3beta in mice leads to hypertrophic
cardiomyopathy secondary to cardiomyoblast hyperproliferation.
Risto Kerkela
Thomas Jefferson University

Lisa Kockeritz
Samuel Lunenfeld Research Institute

Katrina Macaulay
Samuel Lunenfeld Research Institute

Jibin Zhou
Thomas Jefferson University
Follow this and additional works at: https://jdc.jefferson.edu/transmedfp

Bradley W. Doble

Part Lunenfeld
of the Cardiology
Commons
Samuel
Research
Institute

Let us know how access to this document benefits you
See next page for additional authors

Recommended Citation
Kerkela, Risto; Kockeritz, Lisa; Macaulay, Katrina; Zhou, Jibin; Doble, Bradley W.; Beahm, Cara;
Greytak, Sarah; Woulfe, Kathleen; Trivedi, Chinmay M.; Woodgett, James R.; Epstein, Jonathan A.;
Force, Thomas; and Huggins, Gordon S., "Deletion of GSK-3beta in mice leads to hypertrophic
cardiomyopathy secondary to cardiomyoblast hyperproliferation." (2008). Center for
Translational Medicine Faculty Papers. Paper 2.
https://jdc.jefferson.edu/transmedfp/2
This Article is brought to you for free and open access by the Jefferson Digital Commons. The Jefferson Digital
Commons is a service of Thomas Jefferson University's Center for Teaching and Learning (CTL). The Commons is
a showcase for Jefferson books and journals, peer-reviewed scholarly publications, unique historical collections
from the University archives, and teaching tools. The Jefferson Digital Commons allows researchers and interested
readers anywhere in the world to learn about and keep up to date with Jefferson scholarship. This article has been
accepted for inclusion in Center for Translational Medicine Faculty Papers by an authorized administrator of the
Jefferson Digital Commons. For more information, please contact: JeffersonDigitalCommons@jefferson.edu.

Authors
Risto Kerkela, Lisa Kockeritz, Katrina Macaulay, Jibin Zhou, Bradley W. Doble, Cara Beahm, Sarah Greytak,
Kathleen Woulfe, Chinmay M. Trivedi, James R. Woodgett, Jonathan A. Epstein, Thomas Force, and
Gordon S. Huggins

This article is available at Jefferson Digital Commons: https://jdc.jefferson.edu/transmedfp/2

Research article

Deletion of GSK-3β in mice leads to
hypertrophic cardiomyopathy secondary
to cardiomyoblast hyperproliferation
Risto Kerkela,1 Lisa Kockeritz,2 Katrina MacAulay,2 Jibin Zhou,1 Bradley W. Doble,2
Cara Beahm,1 Sarah Greytak,3 Kathleen Woulfe,1 Chinmay M. Trivedi,4
James R. Woodgett,2 Jonathan A. Epstein,4 Thomas Force,1 and Gordon S. Huggins3
1Center for Translational Medicine, Thomas Jefferson University, Philadelphia, Pennsylvania, USA. 2Samuel Lunenfeld Research Institute,
Mount Sinai Hospital, Toronto, Ontario, Canada. 3Molecular Cardiology Research Institute, Tufts Medical Center, Boston, Massachusetts, USA.
4Penn Cardiovascular Institute, University of Pennsylvania, Philadelphia, Pennsylvania, USA.

Based on extensive preclinical data, glycogen synthase kinase–3 (GSK-3) has been proposed to be a viable drug
target for a wide variety of disease states, ranging from diabetes to bipolar disorder. Since these new drugs,
which will be more powerful GSK-3 inhibitors than lithium, may potentially be given to women of childbearing potential, and since it has controversially been suggested that lithium therapy might be linked to congenital cardiac defects, we asked whether GSK-3 family members are required for normal heart development in
mice. We report that terminal cardiomyocyte differentiation was substantially blunted in Gsk3b–/– embryoid
bodies. While GSK-3α–deficient mice were born without a cardiac phenotype, no live-born Gsk3b–/– pups were
recovered. The Gsk3b–/– embryos had a double outlet RV, ventricular septal defects, and hypertrophic myopathy, with near obliteration of the ventricular cavities. The hypertrophic myopathy was caused by cardiomyocyte hyperproliferation without hypertrophy and was associated with increased expression and nuclear
localization of three regulators of proliferation — GATA4, cyclin D1, and c-Myc. These studies, which we
believe are the first in mammals to examine the role of GSK-3α and GSK-3β in the heart using loss-of-function approaches, implicate GSK-3β as a central regulator of embryonic cardiomyocyte proliferation and differentiation, as well as of outflow tract development. Although controversy over the teratogenic effects of
lithium remains, our studies suggest that caution should be exercised in the use of newer, more potent drugs
targeting GSK-3 in women of childbearing age.
Introduction
The factors regulating proliferation of cardiomyocytes during
development have been the focus of many investigations in the
past decade. These studies have identified several growth factors, acting in a paracrine fashion, that regulate cardiac growth
and chamber morphogenesis. Specifically, endothelium-derived
neuregulin-1 (Nrg1), acting via its receptor and coreceptor, the
tyrosine kinases Erb-B4 and Erb-B2, is critical for chamber morphogenesis and trabeculation of the ventricular walls (1–3). Other
studies have identified IGF-1 (4), retinoic acid, FGF9, -16, and -20
(5), and BMP10 (6) as regulators of cardiomyocyte proliferation
during mid-gestation. These factors likely regulate cardiomyocyte
proliferation through transcription factors, including N-myc,
GATA4, T-box genes, and, possibly, nuclear factor of activated
T cells (NF-AT) family members (in particular, NF-ATc3 and
NF-ATc4) (7–11). Signaling pathways connecting growth factors and these downstream mediators of proliferation are poorly
understood. Not surprisingly, the PI3K pathway, which is the primary signaling arm of several growth factor receptors, including
IGF-1, has been found to play a role in cardiomyocyte proliferation ex vivo and in vitro (4, 12, 13). However, it remains unclear
Nonstandard abbreviations used: DORV, double outlet RV; EB, embryoid body;
GSK, glycogen synthase kinase; NF-AT, nuclear factor of activated T cells; TNFR1,
TNF-α receptor–1; VSD, ventricular septal defect.
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whether this is relevant in vivo, which specific components of this
complex pathway might regulate growth, and how they accomplish this, particularly in the developing heart.
The glycogen synthase kinase isoforms GSK-3α and GSK-3β
have nearly identical kinase domains but differ in their N- and
C-terminal sequences (14, 15). These kinases are key regulators of
the canonical Wnt pathway through phosphorylation-mediated
targeting of β-catenin for proteasomal degradation (16–19). The
Wnt/β-catenin pathway plays a central role in endocardial cushion
and atrioventricular valve development via regulating the process
of endothelial-mesenchymal transition (EMT) (16, 19). Indeed,
proper regulation of canonical Wnt pathway components, including dishevelled-2, is required for outflow tract development (20,
21). However, isoform-specific roles for GSK-3α and -3β in Wnt/
β-catenin–regulated heart development are unlikely, since both
kinases are functionally redundant in regulating β-catenin stability and 3 of 4 GSK-3 alleles must be disrupted before an effect on
β-catenin signaling can be found (22).
GSK-3 kinases have also been reported to negatively regulate
several transcription factors and basic cell cycle regulators implicated in heart development, such as D-type cyclins and Myc family
members (23, 24). However, the studies suggesting a role for GSK-3
in regulating these factors are largely based on overexpression
approaches in cultured cell lines, and, recently, some have challenged the putative role played by GSK-3 (25–27).
We believed that determining the role played by GSK-3 in cardiac development was an important issue in and of itself, but the
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Table 1
Expression of differentiation markers in EBs
Marker

WT, n = 3

Gsk3a–/–, n = 3

Nanog
Brachyury
GATA4
Nkx2.5
β-MHC
α-MHC
SERCA2
BNP

2.19 ± 0.16
2.53 ± 0.28
0.88 ± 0.27
2.13 ± 0.74
4.69 ± 0.46
5.69 ± 0.95
2.43 ± 0.15
6.18 ± 0.87

1.82 ± 0.19
3.26 ± 0.66
0.89 ± 0.13
3.13 ± 0.46
2.39 ± 0.56B
3.42 ± 0.45B
1.96 ± 0.24
4.25 ± 0.23

Gsk3b–/–, n = 3
1.57 ± 0.11
0.82 ± 0.18A
0.89 ± 0.03
1.08 ± 0.20
0.93 ± 0.07A,B
0.87 ± 0.17A,B
1.03 ± 0.05A,B
1.18 ± 0.12A,B

Values are arbitrary units (mean ± SEM). AP < 0.05 versus Gsk3a–/–;
BP < 0.05 versus WT. BNP, B-type natriuretic peptide; β-MHC, β–myosin heavy chain; SERCA2, sarcoplasmic reticulum Ca2+-ATPase.

question may take on greater importance given the proposed use
of small molecule inhibitors of GSK-3 in women of childbearing
age who suffer from bipolar disorder. It is estimated that nearly
4% of the US population suffers from bipolar disorder (28), and
inhibition of GSK-3 is believed to play a key role in the therapeutic
response to lithium treatment (29), which has been the mainstay
of therapy for 50 years. Based on the preponderance of evidence
(reviewed in ref. 29), GSK-3 has been identified as a viable target
for treatment of bipolar disorder. Since there is a suggestive link
between lithium therapy and congenital cardiac malformations
(30), the active development of newer GSK-3 inhibitors that are
significantly more potent than lithium increases the importance
of defining the role of GSK-3 in cardiac development.
To determine the role of GSK-3 kinases in general, and specific isoforms in particular, in mammalian heart development,
we studied ES cells and mice deleted for either Gsk3a or Gsk3b.
While the GSK-3α–deficient embryos were born at the expected
frequency and had no cardiac developmental defects, no live-born
GSK-3β–deficient mice were recovered. Some GSK-3β–deficient
embryos died in mid-gestation due to severe liver degeneration, as
previously described (31). However, penetrance of this phenotype
was not uniform, and the majority of animals survived to late gestational periods (32). In these embryos, many of which appeared
grossly normal upon inspection, we demonstrate a profound effect
of deletion of GSK-3β on proliferative growth in the developing
heart and a key role for the kinase in normal development of the
outflow tract. This is the first report to our knowledge of cardiac
development in mice deficient of either GSK-3α or GSK-3β and
should heighten awareness of the potential risks involved in inhibiting these kinases in the developing embryo.
Results
Cardiomyocyte differentiation of GSK-3β–deficient ES cells is abnormal.
To determine the role of the GSK-3 isoforms in cardiomyocyte
differentiation, we induced embryoid body (EB) formation using
the hanging-drop method with the previously characterized WT,
Gsk3a–/–, and Gsk3b–/– ES cell lines (22). Spontaneously contracting
WT and Gsk3a–/– EBs were found after 7 days. However, beating
Gsk3b–/– EBs were not found until day 8. Compared with WT (82
beating per 93 EBs, 88%), there were significantly fewer beating
Gsk3a–/– EBs (66 beating per 90 EBs, 73%; P = 0.01 versus WT) and
many fewer contracting Gsk3b–/– EBs (43 beating per 96 EBs, 44%;
P < 0.0001 versus WT and versus Gsk3a–/–).
3610
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To determine whether the delayed onset of Gsk3b–/– EB contraction correlated with differences in genes upregulated during cardiomyocyte differentiation, quantitative PCR was performed. Similar
levels of Nanog were found in the 3 cell lines after differentiation;
however, brachyury, a marker of mesoderm development, was
reduced in Gsk3b–/– compared with WT and Gsk3a–/– EBs (Table 1).
Expression of the transcription factors GATA4 and Nkx2.5, which
mark the earliest stages of cardiomyocyte differentiation, was similar. In contrast, expression of the contractile proteins α–myosin
heavy chain (α-MHC) and β-MHC, later markers of cardiomyocyte
differentiation, was significantly reduced in the Gsk3–/– EBs, with
the greatest effect found in the Gsk3b–/– EBs (Table 1). Sarcoplasmic
reticulum Ca2+-ATPase (SERCA2), an important regulator of cardiomyocyte contraction whose expression is strongest after birth,
marks late cardiomyocyte differentiation. Expression of SERCA2, as
well as the B-type natriuretic peptide (BNP), was selectively reduced
in Gsk3b–/– EBs. These data, taken together, suggest that GSK-3β is
necessary for late cardiomyocyte differentiation.
GSK-3β–deficient embryos have congenital heart defects. To determine
the role of GSK-3 proteins in cardiac development and to examine
isoform-specific effects, we produced Gsk3a–/– mice by gene targeting and compared their cardiac development with that of the
GSK-3β–deficient mouse. Gsk3a–/– mice are fertile and are born at
expected Mendelian ratios with no cardiac developmental abnormalities (Supplemental Figure 1; supplemental material available
online with this article; doi:10.1172/JCI36245DS1). By comparison, no live-born Gsk3b–/– animals were recovered.
Previously, Gsk3b–/– embryos were found to be susceptible to liver
failure in utero. More recently, however, Liu et al. did not observe a
significant increase in mid-gestational embryonic death in Gsk3b–/–
embryos (32), which would be inconsistent with liver failure. To
explore more deeply the timing of Gsk3b–/– embryo demise, and the
prevalence of liver failure, we genotyped 287 embryos ranging from
E12.5 to E19.5 derived from heterozygote matings. While fewer
Gsk3b–/– mice were found than expected, the number was not significantly different from that predicted for mid- and late-gestational
periods (Table 2). Markedly pale Gsk3b–/– embryos, which are characteristic of liver failure, were infrequently recovered during mid- and
late-gestational periods (32). Thus, GSK-3β, and not GSK-3α, is necessary for survival after birth.
Since liver failure did not explain the lack of viability of Gsk3b–/–
pups, we tested for congenital defects in heart development that
can be responsible for perinatal death. At E13.5, Gsk3b+/+ embryos
showed the expected pattern of cardiac outflow tract septation
(dividing the truncus arteriosus into the aorta and pulmonary
artery), positioning of the aorta over the left ventricle, connection of
the pulmonary artery to the right ventricle, and near or complete closure of the interventricular septum. By comparison, in E13.5–E17.5
Gsk3b–/– embryos, the aorta and pulmonary artery consistently
arose from the RV (double outlet RV [DORV]) and a ventricular
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Table 2
Survival of mutant embryos
Time point

Gsk3b+/+

E12.5–E15.5
E16.5–E19.5

51
23

Gsk3b+/–
99
55

Gsk3b–/–

c2 P value

40
19

NS
NS

Values indicate total number of embryos genotyped at each gestational age.
Volume 118

Number 11

November 2008

research article

Figure 1
Histological analysis of heart development in GSK-3β–deficient mice. Sequential rostral-to-caudal sections from an E15.5 Gsk3b–/– embryo
from the pulmonary valve (top left) to the ventricles (bottom right) (original magnification, ×2.0; scale bar: 0.5 cm). The pulmonary valve and the
pulmonary artery (P) are positioned over the RV (A–C). Below the pulmonary valve, the aorta (A) descends toward the aortic valve (D–F); the
aortic valve is positioned over the RV (G). Caudal to the semilunar valves, the RV and the LV are connected by a VSD (H–K). The location of
the VSD is in the membranous portion of the interventricular septum.

septal defect (VSD) was apparent (Figure 1). DORV and VSD can
be the product of abnormal cardiac cushion development; however,
with the exception of the VSD, the endocardial cushion–derived
valves and septae appeared normal in Gsk3b–/– animals (Figure 2,
A and B). Defects of cardiac neural crest cell migration or function
that produce DORV and VSD commonly also produce abnormal
remodeling of the cardiac outflow tract and aortic arch arteries
(e.g., interrupted aortic arch). However, no abnormalities of great
vessel development were observed in Gsk3b–/– embryos (n = 13). Furthermore, expression of the cardiac neural crest markers plexin A2
and semaphorin 3C was not different in WT and Gsk3b–/– embryos
(Supplemental Figure 2). These results demonstrate that GSK-3β,
and not GSK-3α, is required for normal cardiac outflow tract development and suggest that the DORV is not due to abnormalities of
the endocardial cushions or neural crest.
Gsk3b-null embryos have markedly thickened ventricular walls. The late
gestation stage of embryo development is characterized by remodeling of the ventricular chambers. These changes in heart shape,
The Journal of Clinical Investigation

which we consider an example of physiologic “remodeling,” include
greater organization of the myocardial layers and gross enlargement
of the ventricular cavities to accommodate a larger stroke volume.
While chamber morphogenesis was not different in Gsk3a–/– mice
compared with WT at 2 days after birth (Supplemental Figure 1),
by E15.5 (Figure 1) and at E17.5, Gsk3b–/– embryos displayed markedly thickened LV and RV walls (Figure 2, A–C). Compared with
those of WT littermates, ventricular cavities of Gsk3b–/– embryos
were smaller and nearly filled with cells (Figure 2, A and B). We
also noted pulmonary blood congestion in Gsk3b–/– embryos (Figure 2D), which is consistent with embryonic heart failure, and this
likely contributed to perinatal death.
Previously, GSK-3β deficiency has been shown to sensitize cells
to the effects of TNF (31). To exclude a role for enhanced TNF
sensitivity in the observed myocardial changes, we crossed the
Gsk3b–/– line with mice lacking TNF-α receptor–1 (TNFR1) (33).
As was the case with Gsk3b–/– single-gene knockout, no live-born
double-knockout mice (Gsk3b–/–Tnfr1–/–) were recovered. Further-
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Figure 2
Analysis of ventricular development. H&E-stained sections of Gsk3b+/+ (left) and Gsk3b–/– (right) hearts (original magnification, ×2.5; scale bars:
0.1 mm) including the mitral valve leaflet (A) and the tricuspid valve leaflet (B) (original magnification, ×2.5; scale bars: 0.5 mm). The atrioventricular valve leaflets of Gsk3b–/– embryos showed cellularity, chordal attachment, and dimension comparable to those of control embryos.
By comparison, the LV wall thickness was greatly increased in the Gsk3b–/– embryo hearts. (C) Quantification of thickness of the LV free wall,
interventricular septum, and RV free wall in Gsk3b+/+ (n = 4) and Gsk3b–/– (n = 6) hearts. Error bars indicate mean ± SEM. *P < 0.05 versus WT.
(D) The pulmonary vasculature and parenchyma showed congestion of blood in Gsk3b–/– (right) compared with Gsk3b+/+ (left) embryos (original
magnification, ×1.6; scale bars: 0.5 mm). (E) TNFR1 deficiency does not rescue the cardiac phenotype of Gsk3b–/– embryo hearts. Sections of
Tnfr1–/– (left) and Gsk3b–/–Tnfr1–/– (right) embryos, including the tricuspid valve leaflet (original magnification, ×1.6; scale bars: 0.5 mm).

more, E17.5 double-knockout animals demonstrated increased
myocardial thickness compared with Tnfr1–/– control embryos
(Figure 2E). These studies suggest an isoform-specific role for
GSK-3β in cardiac hypertrophy and outflow tract development
that is independent of TNF signaling.
Cardiomyocyte hyperproliferation accounts for the increased wall thickness
in GSK-3β–deficient hearts. The overwhelming majority of the myocardial cells in Gsk3b–/– embryo hearts stained positive for GATA4 but
negative for the endothelial cell–specific marker isolectin B4 (data
not shown), consistent with hyperproliferation and/or hypertrophy,
specifically of cardiomyocytes, accounting for the increase in wall
thickness. Based on studies employing overexpression of GSK-3β,
it appears that the kinase negatively regulates both physiologic and
pathologic postnatal cardiomyocyte hypertrophy (34–37). To determine whether the loss of GSK-3β caused hypertrophy, we measured
cardiomyocyte size in GSK-3β–deficient embryos, employing staining
with FITC-conjugated wheat germ agglutinin (Supplemental Figure
3A). There was a statistically significant, but very modest, increase in
cardiomyocyte cross-sectional area in the Gsk3b–/– embryos at E15.5
(Supplemental Figure 3B) that was not apparent at E17.5 (data not
shown). Furthermore, while the GSK-3 proteins are critical regulators of glycogen storage, there was no difference in glycogen content
in Gsk3b–/– and WT embryos (Supplemental Figure 3C). Thus, cellular hypertrophy and glycogen accumulation could not account for
the enhanced wall thickness of the Gsk3b–/– embryos at E17.5.
3612
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Since cardiomyocyte hypertrophy did not explain the observed
wall thickening, we explored whether the phenotype could be
secondary to either reduced apoptosis or increased proliferation.
We saw no significant differences between WT and Gsk3b–/– mice
in rates of cardiomyocyte apoptosis as determined by TUNEL
assay (Supplemental Figure 4). In contrast, we observed a marked
increase in levels of phosphorylated histone H3 (an M phase–specific marker) at both E13.5 and E15.5 in the myocardium of Gsk3b–/–
embryos, consistent with enhanced proliferation (Figure 3, A and
B). To determine whether the increased proliferation seen was specifically due to cardiomyocyte proliferation, we costained embryo
sections for both phosphorylated histone H3 and GATA4. The
vast majority of cells (>90%) staining positive for phospho–histone
H3 were also positive for GATA4, suggesting that they were proliferating cardiomyocytes (Figure 3C). Cardiac ECs can also express
GATA4 (38). However, ECs, identified by isolectin B4 staining,
accounted for only 6% and 8% of phospho–histone H3–positive
cells in the myocardium of Gsk3b+/+ and Gsk3b–/– hearts, respectively. Thus, the increased proliferation in the Gsk3b–/– hearts is due to
hyperproliferation of cardiomyocytes and this, in turn, appears to
account for the thickened myocardium at late gestation.
GSK-3β deficiency alters expression and/or nuclear partitioning of cardiac cell cycle regulators. To explore the mechanism by which GSK-3β
deficiency may increase cardiomyocyte proliferation, we examined
GSK-3 targets implicated in heart development for altered expres-
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Figure 3
Increased cardiomyocyte proliferation in GSK-3β–deficient hearts.
(A) Immunofluorescence staining
for nuclear phospho–histone H3
(Ser10) (left panels) in GSK-3β–
deficient (bottom) compared with
WT (top) animals. Merging of the
histone and the DAPI (middle)
stains confirmed nuclear localization of the phospho–histone H3
(Ser10) staining (right panels).
Original magnification, ×40. (B)
Composite mean ± SEM percentage of phospho–histone H3
(Ser10)–staining cells at E13.5 and
E15.5 in the myocardium of WT
(white bars) and GSK-3β–deficient
(back bars) animals.*P < 0.05,
**P < 0.001 versus WT. (C) Coimmunostaining of heart sections with
phospho–histone H3 and GATA4,
a cardiomyocyte marker, demonstrating colocalization in the overlay. Thus, the phospho–histone
H3 (Ser10)–positive cells in the
myocardium are overwhelmingly
GATA4 positive, consistent with
cardiomyocytes. Also shown is
nuclear staining with DAPI. Original
magnification, ×40.

sion and/or nuclear/cytoplasmic partitioning in the Gsk3b–/–
embryos. Because GSK-3 negatively regulates β-catenin, we asked
whether enhanced β-catenin signaling in cardiomyocytes might
account in part for the growth phenotype of the Gsk3b–/– embryos.
However, β-catenin was overwhelmingly associated with the cell
membrane in ventricular myocytes at E13.5 (Supplemental Figure
5A) and E15.5 (data not shown) and in the nucleus of valve-forming regions, irrespective of genotype (Supplemental Figure 5B).
Contradictory reports have appeared addressing whether GSK-3β
regulates stability of various cyclins (23, 25–27). Therefore, we analyzed sections of multiple Gsk3b–/– and Gsk3b+/+ embryonic hearts
with immunohistochemistry, focusing on the amount of cyclin D1
staining present in the nucleus. Indeed, increased cyclin D1 was
present in the nucleus of Gsk3b–/– compared with Gsk3b+/+ embryos.
To determine the significance of this difference, we asked whether
an independent observer could predict the genotype based upon the
level of expression of nuclear cyclin D1. The genotype of 10 of 11
Gsk3b–/– and Gsk3b+/+ heart sections was correctly predicted on the
basis of increased nuclear cyclin D1 staining in the knockout (P < 0.01;
Figure 4A). Thus, our findings support the concept that GSK-3β
does regulate cyclin D1, at least in the developing heart, and provide
one potential mechanism contributing to the hyperproliferative
phenotype. We also examined cyclin E, which has been reported to
The Journal of Clinical Investigation

be regulated by GSK-3β (39), but saw no differences between Gsk3b–/–
and WT littermates (data not shown). Myc family members also
drive cardiomyocyte proliferation, and c-Myc and N-Myc levels
are regulated by GSK-3β (24). The genotype of 9 of 11 heart sections was correctly predicted based on an increase in nuclear c-Myc
(P < 0.05; Figure 4B) but not N-myc (data not shown) in cardiomyocytes of the Gsk3b–/– and Gsk3b+/+ mice. Phosphorylation of NF-ATs
by GSK-3β leads to cytosolic localization (40); however, we could
detect no obvious enhancement of nuclear-localized NF-ATc3
or NF-ATc4 in Gsk3b–/– cardiomyocytes (data not shown).
Finally, we examined GATA4 nuclear partitioning, as a study
employing overexpression of a dominant-negative mutant of GSK-3β
in vitro suggested that GSK-3β regulates nuclear GATA4 levels
(41). We found a marked increase in nuclear-localized GATA4 in
the absence of GSK-3β (Figure 5) and correctly identified the genotype of 16 of 16 heart sections based on the amount of nuclear
GATA4 present (P < 0.01). These data suggest that partitioning
and/or expression of GATA4 is regulated by GSK-3β in vivo.
Inhibition of GSK-3 and GATA4 overexpression drives cardiomyocyte
proliferation. To explore the role of GSK-3 and GATA4 in driving
cardiomyocyte proliferation, we examined the effect of pharmacologic inhibition of GSK-3 and adenovirus-mediated gene
transfer of GATA4 on proliferation of cultured neonatal rat car-

http://www.jci.org

Volume 118

Number 11

November 2008

3613

research article
Figure 4
Altered transcription factor and cell cycle regulator expression and localization in GSK-3β–deficient hearts. (A) Increased nuclear cyclin D1 in
hearts of E15.5 GSK-3β–deficient embryos. Sections were stained with
anti–cyclin D1 antibody (brown) and then counterstained with hematoxylin to identify nuclei (blue). Note the multiple dark brown nuclei
(arrowheads) and the overall increase in cyclin D1 stain and corresponding decrease in intensity of the hematoxylin stain in the GSK-3β–
deficient hearts. Original magnification, ×40. (B) c-Myc expression is
increased in GSK-3β–deficient hearts. Sections from E15.5 embryos
were stained with anti–c-Myc antibody (brown) and then counterstained
with hematoxylin as described above. Note the enhanced brown staining of the nuclei (arrowheads) and the reduction in intensity of the
hematoxylin stain, consistent with increases in nuclear c-Myc expression in the GSK-3β–deficient heart. Original magnification, ×40.

diomyocytes, which retain the ability to proliferate for 2–3 days
after isolation. The GSK-3 inhibitors lithium chloride and 6-bromoindirubin-3ʹ-oxime (BIO) significantly increased proliferation
as determined by phospho–histone H3 staining (Figure 6A). Similarly, even modest overexpression of GATA4 was sufficient to drive
cardiomyocyte proliferation (Figure 6B). These studies confirm a
cell-autonomous effect of GSK-3 inhibition and GATA4 expression on cardiomyocyte proliferation. Consistent with GSK-3β
having several targets regulating cell cycle progression in addition
to GATA4 (e.g., cyclin D1 and c-Myc), GSK-3 inhibition induced
more pronounced proliferation than GATA4 gene transfer.
Discussion
Herein we report that ablation of GSK-3β led to
impaired cardiomyocyte differentiation in ES cells
and to pronounced hyperplasia of cardiomyocytes
during embryonic development, culminating in
a ventricle filled with myocytes. In striking contrast, defects of cardiomyocyte differentiation of
Gsk3a–/– ES cells were less severe, and cardiac development in the Gsk3a–/– mouse was normal. These
data clearly demonstrate distinct developmental
roles of the two GSK-3 isoforms. Furthermore, our
studies identify disordered regulation of GATA4,
cyclin D1, and c-Myc, three factors known to play
a role in cardiomyocyte proliferation during development, in the Gsk3b–/– heart and implicate these
factors in the hyperproliferative phenotype.
We detected similar expression of GATA4 and
Nkx2.5 in GSK-3–deficient EBs, which suggests
that regulation of early cardiomyocyte differentiation is not specific to either GSK-3 isoform.
This finding may be explained by the fact that
β-catenin signaling, which promotes induction of
the cardiomyocyte fate during the early stage of ES
cell differentiation (42), is preserved in GSK-3β–
3614

and GSK-3α–deficient EBs. Indeed, the lack of an increase in
cytosolic or nuclear β-catenin in cardiomyocytes of Gsk3b–/– animals is consistent with the finding that Gsk3a can fully compensate for loss of Gsk3b in the regulation of β-catenin (22). By
comparison, EB contraction and expression of late markers of cardiomyocyte differentiation were prominently reduced in GSK-3β–
deficient compared with GSK-3α–deficient and WT EBs. The pronounced inhibition of cardiomyocyte differentiation in the setting
of GSK-3β deficiency suggests that GSK-3β–selective regulation of
transcription factors or cell cycle regulators is critical for the late
stage of cardiomyocyte differentiation.
Differences in GSK-3α and -3β signaling in cardiomyocyte differentiation are even more apparent in heart development. Although
atrioventricular and semilunar valve development was normal in
the Gsk3b–/– mouse, outflow tract and septation defects were evident (DORV and VSD). The finding of DORV in GSK-3β–deficient
embryos may be interpreted as a nonspecific finding, as septation of
the great vessels, creation of AV valves and outflow tracts, and closure of the VSD are regulated by cells of the endocardial cushions
and neural crest. While abnormalities of neural crest could explain
the DORV in GSK-3β–deficient embryos (and only a tissue-specific
knockout in neural crest cells could definitively address this), we

Figure 5
Increased nuclear GATA4 expression in GSK-3β–deficient hearts. GATA4 staining (left)
was located over nuclei in the hearts of E13.5 embryos stained by DAPI (center) in
merged images (right). Original magnification, ×40.
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Figure 6
GATA4 overexpression drives cardiomyocyte proliferation. (A) GSK-3
inhibition increases neonatal rat ventricular myocyte (NRVM) proliferation. Shown is the mean ± SEM percentage of phospho–histone H3
(Ser10)–staining cells 20 hours following LiCl and 6-bromoindirubin3ʹ-oxime (BIO) treatment at the indicated concentrations. (B) GATA4
overexpression induces NRVM proliferation. Immunoblot of lysates
from NRVMs infected with adenovirus encoding LacZ (left 2 lanes) or
GATA4 (right 2 lanes). NRVMs were treated with 100 viral particles per
cell (first and third lanes) or 200 particles per cell (second and fourth
lanes). NRVMs plated onto glass coverslips were stained for phospho–
histone H3 (Ser10) 48 hours after infection of cells with adenoviruses
(200 viral particles per cell) encoding GATA4 (Ad-GATA4) or LacZ
(Ad-LacZ). Shown is the mean ± SEM percentage of phospho–histone
H3 (Ser10)–staining cells following Ad-LacZ or Ad-GATA4 infection. *P < 0.05, **P < 0.01, ***P < 0.001 versus vehicle control (Ctrl);
†P < 0.001 versus Ad-LacZ.

saw no evidence of improper septation of the great vessels, which
is a common feature of neural crest defects. Furthermore, spatial
migration of neural crest cells appeared normal. Enlargement of the
endocardial cushions that impair normal rotation of the developing outflow tract can produce DORV. However, since there was no
abnormality in valve development (which requires intact β-catenin
signaling for the EMT), we consider a selective defect in the cushion
cells to be unlikely. We considered that the marked distortion of LV
geometry secondary to the cardiomyocyte hyperproliferation may
have given rise to the DORV by impairing normal rotation of the
outflow tract; however, the DORV was present before noticeable
differences in ventricular wall thickness (data not shown).
Our finding that GSK-3α is not required for mouse development is in contrast to observations in zebrafish, in which morpholino oligonucleotide–mediated knockdown of GSK-3α produced
severe axial developmental defects and death (43). Furthermore,
while knockdown of either zebrafish GSK-3 isoform produced
thin hearts and pericardial edema, we only found heart defects in
Gsk3b–/– embryos. Finally, while zebrafish GSK-3α is required for
cardiomyocyte survival, in striking contrast, we found that Gsk3b–/–
mouse embryos showed increased cardiomyocyte proliferation. We
cannot reconcile the differences between the zebrafish and mouse
loss-of-function studies; however, we speculate that differences in
amino acid sequences flanking the serine/threonine kinase domain
(44), altered substrate availability, or differences in the developmental expression pattern may account for unique roles for the GSK-3
isoforms in zebrafish compared with mammals. Despite these differences, morpholino oligonucleotide targeting of zebrafish GSK-3β
produced abnormalities of heart tube jogging and outflow tract
positioning (43) that may provide insight into the DORV observed
in Gsk3b–/– mice. The zebrafish outflow abnormalities correlated
with abnormal lefty and BMP4 expression, suggesting an important role for GSK-3β in left-right patterning. Our data demonstrating DORV likewise suggest a requirement for GSK-3β in outflow
tract development of the mammalian heart.
The striking enlargement of ventricular walls in late gestational
periods, virtually filling the ventricular cavities, must be viewed in
comparison to findings of studies by our group (34, 45) and othThe Journal of Clinical Investigation

ers (35–37, 46) that have employed overexpression approaches to
suggest that GSK-3β is a potent negative regulator of cardiomyocyte growth. The growth that has been studied to date is postnatal
growth, the vast majority of which is via hypertrophy rather than
hyperplasia, since postnatal cardiomyocytes are generally unable to
reenter the cell cycle except under extreme circumstances. Indeed,
because cardiomyocyte cross-sectional areas in Gsk3b–/– and control
E17.5 embryos were similar, the increased ventricular wall thickness is not the result of cardiomyocyte hypertrophy. Herein we
identify a key role for GSK-3β in regulating hyperplastic growth of
the developing heart. Because both the left and right ventricles were
excessively cellular, relative to the chamber dimension, this finding is much more likely to be due to effects of deletion of GSK-3β
than a response to an epigenetic influence (e.g., constrained outflow). Similarly, pharmacologic inhibition of GSK-3 also increased
cardiomyocyte proliferation. Withdrawal from the cell cycle is
required for the late and terminal stages of cardiomyocyte differentiation (47). Thus, active cycling of the Gsk3b–/– embryo cardiomyocytes is likely one important factor contributing to inhibition
of their terminal differentiation.
The most striking consequences of GSK-3β deficiency that likely
drive cardiomyocyte proliferation are increases in nuclear GATA4,
cyclin D1, and c-Myc, all of which, based on our findings, appear to
be targets of GSK-3β in vivo. GSK-3–mediated phosphorylation of
cyclin D1 at Thr286 has been proposed to trigger nuclear export of
cyclin D1 and priming of cyclin D1 for ubiquitination and degradation (23), though this is a subject of debate (25). Our data, from
studies employing genetic loss of function of GSK-3β in vivo, support a role for GSK-3β as a regulator of cyclin D1 nuclear/cytoplasmic partitioning and degradation. Of note, the phenotype of the
GSK-3β knockout is virtually the opposite of that of mice deleted
for cyclins D1/D2/D3 or deleted for cyclin D partners Cdk2/Cdk4,
which have marked thinning of the walls (48, 49). Interestingly,
most tissues in the cyclin D1/D2/D3–deficient mouse had normal
proliferation rates, while cardiomyocytes and hematopoietic stem
cells appeared to be relatively unique in their dependence on D-type
cyclins for driving proliferation (48).
Although GSK-3β deficiency affects several cell cycle regulators, its
regulation of GATA-dependent signaling may be a critical contributor to cardiomyocyte proliferation. GATA4/GATA6 compound heterozygosity (50) and cardiomyocyte-specific knockout of GATA4 (11)
produce heart developmental abnormalities characterized by reduced
cardiomyocyte proliferation. Because the increased wall thickness in
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Gsk3b–/– embryos is related to hyperplasia, rather than hypertrophy,
we propose that increased GATA4 nuclear accumulation in Gsk3b–/–
embryos can be expected to drive proliferation. Indeed, deletion of
GSK-3β likely produces a GATA4 gain of function, in vivo, which
drives proliferation. Our conclusion is supported by the finding that
forced GATA4 expression (and GSK-3 inhibition) increases neonatal
cardiomyocyte proliferation. Our results suggest that GSK-3β–mediated phosphorylation and inhibition of GATA4 and other regulators
of cellular proliferation are necessary to restrict the number of cardiomyocytes during late gestational periods of heart development,
which allows for completion of cardiomyocyte differentiation.
GSK-3 has been proposed as a viable target in numerous disease states, including ischemic injury of the heart and brain (51),
inflammation (52), diabetes (53), Alzheimer disease (51), and bipolar disorders (29). While lithium is currently the only available
approved drug that can inhibit GSK-3, numerous inhibitors with
greater potency and specificity are in development (54). The issue
of whether lithium, and by extension GSK-3 inhibition, causes congenital heart defects has been debated in the literature for more
than 20 years because early retrospective analyses that reported
high rates of congenital heart defects in the setting of lithium treatment were flawed (30). A more recent report confirmed a marginally increased risk for a cardiac defect after maternal use of lithium
(55), and administration of lithium to animal models at very early
gestational stages produces heart defects (56). However, it has been
difficult to determine whether the heart defects observed in these
lithium studies can be extrapolated to newer, more potent GSK-3
inhibitors for several reasons. First, lithium levels achieved in
patients are only approximately 1 mM, and this causes (at physiological levels of Mg2+) only an approximately 25% inhibition of total
GSK-3 activity (i.e., approximately equal to deletion of 1 allele of
either GSK-3α or GSK-3β) (57). Second, lithium has several targets
in addition to GSK-3, including Akt (which is activated by lithium
and obviously has numerous targets in addition to GSK-3) and
inositol monophosphatases (58). Indeed, depletion of intracellular
inositol has been suggested to mediate the anti-manic effects of
lithium (59). More recently, lithium has been shown to disrupt a
complex consisting of Akt, GSK-3, protein phosphatase 2a, and
β-arrestin (60). Thus, lithium has effects well beyond simply inhibiting GSK-3, making it nearly impossible to ascribe specific effects of
lithium to one specific target and completely impossible to ascribe
effects to one specific isoform. We believe that our findings using
genetically targeted mice bring clarity to the central issue: that inhibition of GSK-3β in the developing heart might be expected to lead
to cardiac developmental abnormalities.
In summary, we have identified GSK-3β as a central regulator of
cardiomyocyte proliferation and differentiation during embryonic
heart development, mediated, at least in part, through its effects
on 2 transcription factors and 1 cell cycle regulator. Deficits of
ventricular remodeling of Gsk3b–/– animals are likely secondary to
the requirement of GSK-3β to restrict myocardial cell number, but
GSK-3β may also have a more direct role in maturation of the ventricle. The requirement for GSK-3β in heart development raises the
consideration that mutations of GSK-3β may contribute to cases
of DORV and VSD as well as LV hypertrophy in humans.
Methods
EB assay. WT, Gsk3a–/–, and Gsk3b–/– ES cell lines, which were previously
described (22), were maintained in Knockout DMEM supplemented with
15% FBS (Hyclone), nonessential amino acids, GlutaMAX-I (Invitrogen),
3616
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2-mercaptoethanol, and 1,000 U/ml ESGRO (Chemicon). Differentiation
medium for the production of embryoid bodies was embryonic stem cell
maintenance medium with the serum content reduced to 5% and no ESGRO
supplementation. EBs were propagated in hanging drops for 3 days and were
then transferred to ultra-low binding 96-well dishes (Corning) and cultured
with differentiation medium that was replenished every 2 days, as previously
described (22). The EBs were examined for spontaneous beating daily. For
each cell line, 3 pools of EBs were collected for expression analysis.
Quantitative real-time RT-PCR. cDNA was synthesized from 1 μg total
RNA using SuperScript III reverse transcriptase and oligo-dT primers
(Invitrogen). For real-time PCR amplification, cDNA was diluted 1:100,
and 1 μl was used for each PCR amplification in triplicate with SYBR
Green PCR Master Mix (Applied Biosystems) and 1 μM transcript-specific primer (Supplemental Methods). Amplification and analysis were
performed using an Applied Biosystems 7900 real-time PCR machine and
SDS 2.3 software (Applied Biosystems). Products were sequenced to verify
specificity of the primers. PCR efficiency was calculated from the slope of
the respective standard. Fold changes in gene expression were determined
using the Pfaffl method (61) and normalized to GAPDH after correcting
for differences in amplification efficiency.
GSK-3–deficient mice. The generation of Gsk3b–/– mice has been previously
described (31). Gsk3a–/– mice were generated by insertion of loxP sites flanking exon 2 of Gsk3a through homologous recombination with an engineered
targeting construct. Germline deletion of exon 2 was accomplished by crossing the floxed mice with a pCAGG-Cre deleter strain (62) as described previously (22). By breeding Cre-deleted GSK-3α heterozygous animals together,
we generated Gsk3a-knockout, Gsk3a-heterozygous, and WT littermate control mice. In contrast to Gsk3b–/– embryos, which die late in gestation or
immediately at birth, Gsk3a–/– mice were both viable and fertile. The genotype of embryos harvested following timed mating of heterozygote animals
was determined by PCR as described previously (22, 31). TNFR1-deficient
mice kindly provided by Tak Mak (33) were crossed with Gsk3b+/– mice to
produce Gsk3b–/–Tnfr1–/– double-knockout and Tnfr1–/– control embryos. All
animal experiments were approved by the Animal Care Committees of the
Toronto Centre for Phenogenomics and the Ontario Cancer Institute under
the auspices of the University of Toronto.
Cell size measurement. Cardiomyocyte cross-sectional area in E15.5 and E17.5
embryos was measured from 5-μm-thick heart sections that had been stained
with FITC-conjugated wheat germ agglutinin as previously described (63),
using OpenLab software–(Improvision). Only myocytes that were round (i.e.,
were cut in cross section) were included in the analysis. An observer blind to
the genotypes of the embryos performed the measurements.
Histological analysis. Embryos were fixed for 18–24 hours in 4%
paraformaldehyde at 4°C, dehydrated in increasing concentrations of ethanol, and embedded in paraffin. Transverse and frontal sections were cut at
5 μm through the thorax and stained with H&E by standard methods. To
determine the orientation of anatomic structures and analysis of embryonic
heart development, serial sections through the heart and great vessel regions
were imaged with an AxioCam MRc digital camera on a Zeiss Stemi 2000-c
stereomicroscope. Each serial image was compiled to allow for analysis of
heart chamber, valve, and great vessel orientation. Wall thickness was measured using the Image-Pro 6.2 program (Media Cybernetics) calibrated to a
reference marker captured at the same magnification. Embryo sections that
included ventricular cavities, the LV free wall, the interventricular septum,
and the RV free wall were selected for wall thickness measurement. The mean
wall thickness from 4 serial sections was determined for each embryo.
Immunostaining. The sections were deparaffinized in xylenes, hydrated
through alcohol series, and washed with water. Antigen retrieval was performed by boiling the samples in sodium citrate solution 3 times for 5 minutes. The endogenous peroxidase activity was quenched by incubating the
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sections in 3% H2O2 for 10 minutes. Next, the sections were blocked with
a blocking solution containing 2% BSA, 0.2% horse serum in PBS supplemented with 0.2% NP-40. The primary antibody was added in blocking solution, and the samples were incubated overnight. For immunofluorescence,
the sections were incubated with fluorescein-conjugated secondary antibody (Invitrogen) together with DAPI for 1 hour at room temperature and
were then washed. Coverslips were secured with Immu-Mount (Thermo
Electron). For immunocytochemistry, the sections were incubated with
biotin-conjugated secondary antibody (BD) for 30 minutes at room temperature, washed, and incubated for 30 minutes with ABC reagent (Vector Laboratories). The sections were then washed and incubated in DAB
solution (Zymed, Invitrogen) for 3 minutes and counterstained with hematoxylin (Zymed, Invitrogen). Finally, the slides were dehydrated, cleared in
xylenes, and mounted with Permount (Biomeda). Antibody against phospho–histone H3 (Ser10) was from Upstate, β-catenin antibody was from
BD, and the other antibodies were from Santa Cruz Biotechnology Inc.
SPOT Imaging software (Diagnostic Instruments Inc.) was used to
record immunohistochemistry images, and OpenLab or NIS Elements
software was used to record immunofluorescence images.
Cardiomyocyte proliferation assay. Primary cultures of neonatal rat ventricular myocytes (NRVMs) were prepared from 2- to 4-day-old Sprague-Dawley
rats as previously described (45). The cells were plated onto laminin-coated
glass coverslips for immunofluorescence studies or onto Primaria cell culture dishes (BD) for immunoblotting. Following desired treatments, the
cells were either fixed with 4% paraformaldehyde, blocked with blocking
solution, and stained for phospho–histone H3 (Ser10) as described above
or lysed for immunoblotting as described previously (45).
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